Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 74
Filtrar
1.
Cytokine ; 168: 156236, 2023 08.
Artigo em Inglês | MEDLINE | ID: mdl-37257306

RESUMO

The matrix metalloproteinases (MMPs) are engaged in the degradation and remodeling of the extracellular matrix and vessels, allowing the progression of pathological processes. Recent studies pointed that MMP -2 and -9 are promising visceral leishmaniasis biomarkers. Thus, the present studystudy aimed to review published scientific literature related to MMP-2 and -9 activity on canine visceral leishmaniasis (CVL). The review followed the PRISMA method, searching for articles in ScienceDirect, PubMed, Scopus, Lilacs, Medline and Google Scholar from inception until 20 March 2022 by employing the following terms: "dog", "matrix metalloproteinases" and "Visceral Leishmaniasis" or "Kala Azar". The selected articles were read in full and only those consistent with the eligibility criteria were included in the review. Of 238 articles from the initial search, only five were deemed eligible, which were conducted between 2010 and 2018. All studies were performed in Brazil. It was observed that there was a higher expression of proMMP-2 in cerebrospinal (CS) fluid and serum and active MMP-2 in different skin areas, mainly in high parasite load areas. As for MMP-9, the pro and active forms were both expressed in CS fluid, serum and different skin areas. The MMP-2 can be considered a biomarker of bad prognostic as it plays an inflammatory role with a greater release in the initial phase of the disease, where MMP-9 is perceived in the chronic phase of CVL. Future research on the subject with greater methodological rigor and bigger sample sizes are mandatory to clarify the role of MMPs on disease progression.


Assuntos
Leishmaniose Visceral , Cães , Biomarcadores , Leishmaniose Visceral/enzimologia , Metaloproteinase 2 da Matriz/metabolismo , Metaloproteinase 9 da Matriz/metabolismo , Fatores de Risco , Animais
2.
Curr Drug Targets ; 21(11): 1105-1129, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-32321399

RESUMO

Leishmaniasis is one of the six entities on the list of most important diseases of the World Health Organization/Tropical Disease Research (WHO/TDR). After Malaria, it is one of the most prevalent and lethal parasitic diseases. VL is the fatal form of this disease, especially if left untreated. The drugs that are currently available for the treatment of VL are expensive, toxic, or no longer effective, especially in endemic regions. Currently, no vaccine has been developed to immunize humans against VL. The major problems with the current drugs are the development of resistance and their adverse effects. Therefore, there is a strong urge to research and design drugs that have better efficacies and low toxicities as compared to current chemotherapeutic drugs. Leishmania has various enzymes involved in its metabolic pathways, which are unique to either the same genus or trypanosomatids, making them a very suitable, attractive and novel target sites for drug development. One of the significant pathways unique to trypanosomatids is the thiol metabolism pathway, which is involved in the maintenance of redox homeostasis as well as protection of the parasite in the macrophage from oxidative stress-induced damage. In this review the several pathways, their essential enzymes as well as the proposed changes in the parasites due to drug resistance have been discussed to help to understand the most suitable drug target. The thiol metabolism pathway is discussed in detail, providing evidence of this pathway being the most favorable choice for drug targeting in VL.


Assuntos
Leishmania/metabolismo , Leishmaniose Visceral/tratamento farmacológico , Leishmaniose Visceral/enzimologia , Animais , Antiprotozoários/farmacologia , Resistência a Medicamentos/fisiologia , Humanos , Leishmania/efeitos dos fármacos , Leishmaniose Visceral/parasitologia , Metabolismo/fisiologia , Compostos de Sulfidrila/metabolismo
3.
Chem Biol Drug Des ; 93(6): 1050-1060, 2019 06.
Artigo em Inglês | MEDLINE | ID: mdl-30891955

RESUMO

Visceral leishmaniasis affects millions of people worldwide in areas where Leishmania donovani is endemic. The protozoan species serves a greater threat as it has gradually evolved drug resistance whereby requiring newer approaches to treat the infection. State-of-art techniques are mostly directed toward finding better targets extracted from the available proteome data. In light of recent computational advancements, we ascertain and validate one such target, adenylosuccinate lyase (ADSL) by implementation of in-silico methods which led to the identification of critical amino acid residues that affects its functional attributes. Our target selection was based on comprehensive topological analysis of a knowledge-based protein-protein interaction network. Subsequently, mutations were incorporated and the dynamic behavior of mutated and native proteins was traced using MD simulations for a total time span of 600 ns. Comparative analysis of the native and mutated structures exhibited perceptible changes in the ligand-bound catalytic region with respect to time. The unfavorable changes in the orientations of specific catalytic residues, His118 and His196, induced by generated mutations reduce the enzyme specificity. In summary, this integrative approach is able to select a target against pathogen, identify crucial residues, and challenge its functionality through the selected mutations.


Assuntos
Adenilossuccinato Liase/metabolismo , Leishmaniose Visceral/enzimologia , Simulação de Dinâmica Molecular , Mutação , Biologia de Sistemas , Animais , Leishmania donovani/patogenicidade , Leishmaniose Visceral/parasitologia , Ligação Proteica
4.
Int J Biol Macromol ; 124: 291-303, 2019 Mar 01.
Artigo em Inglês | MEDLINE | ID: mdl-30452983

RESUMO

The visceral leishmaniasis is caused by L. donovani, a neglected tropical disease with an estimated number of 500,000 cases worldwide. Apart from the absence of effective vaccine, the available drugs have limitations like toxic side effects and emergence of drug resistance. The genome of Leishmania is remarkably challenged by the oxidative stress present inside the human macrophage. To maintain genomic integrity, a number of specialized DNA repair pathways assist in the recognition and repair of damaged DNA. In general, Base Excision Repair (BER) plays an essential role in the maintenance of genomic stability. We demonstrate here that the treatment of L. donovani with oxidative agents causes DNA damage and upregulation of Polß. On the other hand, parasite overexpressing Polß shows more resistance against Amp B, H2O2 and menadione as compared to wild type cells. We also observed a higher infectivity in the parasites that overexpress Polß. The upregulation of Polß was also found in stationary phase and axenic amastigote of L. donovani. Overall, we propose that Polß is crucial for infectivity and survival of the parasite. Discovery of specific inhibitors against Polß could offer an attractive strategy against leishmaniasis.


Assuntos
DNA Polimerase beta/genética , Resistência a Medicamentos/genética , Leishmania donovani/enzimologia , Leishmaniose Visceral/genética , Animais , Dano ao DNA/efeitos dos fármacos , DNA Polimerase beta/química , Replicação do DNA/genética , Humanos , Peróxido de Hidrogênio/química , Leishmania donovani/efeitos dos fármacos , Leishmania donovani/patogenicidade , Leishmaniose Visceral/enzimologia , Leishmaniose Visceral/parasitologia , Oxirredução , Estresse Oxidativo/efeitos dos fármacos
5.
PLoS Negl Trop Dis ; 12(7): e0006646, 2018 07.
Artigo em Inglês | MEDLINE | ID: mdl-30036391

RESUMO

BACKGROUND: Endoplasmic reticulum (ER) stress generated unfolded stress response (UPR) is a basic survival mechanism which protects cell under unfavourable conditions. Leishmania parasite modulates host macrophages in various ways to ensure its survival. Modulation of PI3K-Akt pathway in delayed apoptotic induction of host; enables parasite to stabilize the infection for further propagation. METHODOLOGY: Infected RAW macrophages were exposed to campothecin or thagsigargin and phosphorylation status of PERK, Akt, BAD and Cyt-C was determined through western blotting using phospho specific antibody. Expression at transcriptional level for cIAP1 &2, ATF4, CHOP, ATF3, HO-1 and sXBP1 was determined using real time PCR. For inhibition studies, RAW macrophages were pre-treated with PERK inhibitor GSK2606414 before infection. FINDINGS: Our studies in RAW macrophages showed that induction of host UPR against L.donovani infection activates Akt mediated pathway which delays apoptotic induction of the host. Moreover, Leishmania infection results in phosphorylation and activation of host PERK enzyme and increased transcription of genes of inhibitor of apoptosis gene family (cIAP) mRNA. In our inhibition studies, we found that inhibition of infection induced PERK phosphorylation under apoptotic inducers reduces the Akt phosphorylation and fails to activate further downstream molecules involved in protection against apoptosis. Also, inhibition of PERK phosphorylation under oxidative exposure leads to increased Nitric Oxide production. Simultaneously, decreased transcription of cIAP mRNA upon PERK phosphorylation fates the host cell towards apoptosis hence decreased infection rate. CONCLUSION: Overall the findings from the study suggests that Leishmania modulated host UPR and PERK phosphorylation delays apoptotic induction in host macrophage, hence supports parasite invasion at early stages of infection.


Assuntos
Apoptose , Leishmania donovani/fisiologia , Leishmaniose Visceral/enzimologia , Leishmaniose Visceral/fisiopatologia , Macrófagos/parasitologia , Resposta a Proteínas não Dobradas , eIF-2 Quinase/metabolismo , Animais , Estresse do Retículo Endoplasmático , Interações Hospedeiro-Parasita , Humanos , Proteínas Inibidoras de Apoptose/genética , Proteínas Inibidoras de Apoptose/metabolismo , Leishmania donovani/genética , Leishmaniose Visceral/parasitologia , Macrófagos/enzimologia , Camundongos , Fosforilação , Células RAW 264.7 , eIF-2 Quinase/genética
6.
Microbes Infect ; 20(2): 111-121, 2018 02.
Artigo em Inglês | MEDLINE | ID: mdl-29133249

RESUMO

DUSP4, an inducible protein has a substrate specificity toward ERK1/2, a component of MAP kinase which is enhanced during Leishmania infection. The DUSP4-/- mice show increased susceptibility towards the infection caused by Toxoplasma gondii and Leishmania mexicana. These observations emphatically established the fact that unlike DUSP1, DUSP4 has host protective role. In our study, it has been Leishmania donovani, the causative agent of visceral leishmaniasis (VL) significantly reduced the expression of DUSP4 during infection. In order to find out the host protective role of DUSP4 in macrophages during VL, we silenced DUSP4 prior to infection and the parasite number within macrophage was counted. Under DUSP4 knock-down condition, phosphorylation of p38 MAPK and generation of pro-inflammatory response like IL-12, TNF-α, and iNOS was decreased significantly. Silencing DUSP4 promoted the phosphorylation of ERK1/2 and the generation of anti-inflammatory response like- IL-10, TGF-ß with increased Arginase-1 and Cox-2 activity. Glycyrrhizic Acid (GA), an immunomodulator, already known to suppress L. donovani infection, found to up-regulate DUSP4 expression during L. donovani infection. On the other hand, GA failed to increase Th1 cytokine production and decrease Th2 response during DUSP4 knock-down condition suggesting the key role of DUSP4 while providing protection during L. donovani infection.


Assuntos
Anti-Inflamatórios/farmacologia , Ácido Glicirrízico/farmacologia , Fatores Imunológicos/farmacologia , Leishmaniose Visceral/imunologia , Proteínas Tirosina Fosfatases/metabolismo , Animais , Anti-Inflamatórios/administração & dosagem , Citocinas/genética , Regulação da Expressão Gênica/efeitos dos fármacos , Ácido Glicirrízico/administração & dosagem , Humanos , Fatores Imunológicos/administração & dosagem , Imunomodulação , Leishmania donovani/fisiologia , Leishmaniose Visceral/enzimologia , Leishmaniose Visceral/parasitologia , Macrófagos/imunologia , Macrófagos/parasitologia , Camundongos , Camundongos Endogâmicos BALB C , Óxido Nítrico/análise , Fosforilação/efeitos dos fármacos , Proteínas Tirosina Fosfatases/deficiência , Proteínas Tirosina Fosfatases/genética , RNA Interferente Pequeno/administração & dosagem , Células THP-1 , Células Th1/metabolismo , Células Th2/metabolismo
7.
Free Radic Biol Med ; 106: 10-23, 2017 05.
Artigo em Inglês | MEDLINE | ID: mdl-28179112

RESUMO

Exploration of metabolons as viable drug target is rare in kinetoplastid biology. Here we present a novel protein-protein interaction among Glucose-6-phosphate dehydrogenase (LdG6PDH) and Trypanothione reductase (LdTryR) of Leishmania donovani displaying interconnection between central glucose metabolism and thiol metabolism of this parasite. Digitonin fractionation patterns observed through immunoblotting indicated localisation of both LdG6PDH and LdTryR in cytosol. In-silico and in-vitro interaction observed by size exclusion chromatography, co-purification, pull-down assay and spectrofluorimetric analysis revealed LdG6PDH and LdTryR physically interact with each other in a NADPH dependent manner. Coupled enzymatic assay displayed that NADPH generation was severely impaired by addition of SbIII, AsIII and TeIV extraneously, which hint towards metalloid driven structural changes of the interacting proteins. Co-purification patterns and pull-down assays also depicted that metalloids (SbIII, AsIII and TeIV) hinder the in-vitro interaction of these two enzymes. Surprisingly, metalloids at sub-lethal concentrations induced the in-vivo interaction of LdG6PDH and LdTryR, as analyzed by pull-down assays and fluorescence microscopy signifying protection against metalloid mediated ROS. Inhibition of LdTryR by thioridazine in LdG6PDH-/- parasites resulted in metalloid induced apoptotic death of the parasites due to abrupt fall in reduced thiol content, disrupted NADPH/NADP+ homeostasis and lethal oxidative stress. Interestingly, clinical isolates of L.donovani resistant to SAG exhibited enhanced interaction between LdG6PDH and LdTryR and showed cross resistivity towards AsIII and TeIV. Thus, our findings propose the metabolon of LdG6PDH and LdTryR as an alternate therapeutic target and provide mechanistic insight about metalloid resistance in Visceral Leishmaniasis.


Assuntos
Glucosefosfato Desidrogenase/metabolismo , Leishmania donovani/efeitos dos fármacos , Leishmaniose Visceral/tratamento farmacológico , NADH NADPH Oxirredutases/metabolismo , Estresse Oxidativo/efeitos dos fármacos , Animais , Antimônio/farmacologia , Arsênio/farmacologia , Citosol/efeitos dos fármacos , Resistência a Medicamentos/efeitos dos fármacos , Glucosefosfato Desidrogenase/química , Humanos , Leishmania donovani/metabolismo , Leishmania donovani/patogenicidade , Leishmaniose Visceral/enzimologia , Leishmaniose Visceral/parasitologia , Metaloides/toxicidade , NADH NADPH Oxirredutases/química , Conformação Proteica/efeitos dos fármacos , Espécies Reativas de Oxigênio , Telúrio/farmacologia
8.
Acta Parasitol ; 61(3): 645-9, 2016 Sep 01.
Artigo em Inglês | MEDLINE | ID: mdl-27447233

RESUMO

Adenosine deaminase (ADA) which degrades adenosine to inosine, is known to be pro-inflammatory molecule in many diseases. Adenosine suppresses the functioning of the immune system and thus promotes dissemination of the parasite. In our previous finding, the level of soluble ADA in serum of visceral leishmaniasis (VL) was found to be increased as compared to healthy controls. However, it cannot be fairly interpreted unless their level is demonstrated at the disease site, where the parasite resides. We designed this study to correlate the level of soluble ADA (sADA) with parasitic load at the disease site i.e. bone marrow (BM). We found increased levels of sADA in BM as compared to the unaffected BM. Furthermore, a significant inverse correlation is observed between the parasite load and level of sADA at the disease site.


Assuntos
Adenosina Desaminase/metabolismo , Medula Óssea/enzimologia , Leishmania donovani/fisiologia , Leishmaniose Visceral/enzimologia , Adolescente , Adulto , Animais , Humanos , Leishmaniose Visceral/genética , Leishmaniose Visceral/parasitologia , Carga Parasitária , Adulto Jovem
9.
J Biol Chem ; 291(34): 17754-71, 2016 08 19.
Artigo em Inglês | MEDLINE | ID: mdl-27382051

RESUMO

Aminoacyl-tRNA synthetases (aaRSs) are housekeeping enzymes essential for protein synthesis. Apart from their parent aminoacylation activity, several aaRSs perform non-canonical functions in diverse biological processes. The present study explores the twin attributes of Leishmania tyrosyl-tRNA synthetase (LdTyrRS) namely, aminoacylation, and as a mimic of host CXC chemokine. Leishmania donovani is a protozoan parasite. Its genome encodes a single copy of tyrosyl-tRNA synthetase. We first tested the canonical aminoacylation role of LdTyrRS. The recombinant protein was expressed, and its kinetic parameters were determined by aminoacylation assay. To study the physiological role of LdTyrRS in Leishmania, gene deletion mutations were attempted via targeted gene replacement. The heterozygous mutants showed slower growth kinetics and exhibited attenuated virulence. LdTyrRS appears to be an essential gene as the chromosomal null mutants did not survive. Our data also highlights the non-canonical function of L. donovani tyrosyl-tRNA synthetase. We show that LdTyrRS protein is present in the cytoplasm and exits from the parasite cytoplasm into the extracellular medium. The released LdTyrRS functions as a neutrophil chemoattractant. We further show that LdTyrRS specifically binds to host macrophages with its ELR (Glu-Leu-Arg) peptide motif. The ELR-CXCR2 receptor interaction mediates this binding. This interaction triggers enhanced secretion of the proinflammatory cytokines TNF-α and IL-6 by host macrophages. Our data indicates a possible immunomodulating role of LdTyrRS in Leishmania infection. This study provides a platform to explore LdTyrRS as a potential target for drug development.


Assuntos
Quimiocinas CXC/metabolismo , Leishmania donovani/enzimologia , Leishmaniose Visceral/enzimologia , Macrófagos/metabolismo , Mimetismo Molecular , Proteínas de Protozoários/metabolismo , Tirosina-tRNA Ligase/metabolismo , Motivos de Aminoácidos , Animais , Quimiocinas CXC/genética , Quimiocinas CXC/imunologia , Citoplasma/enzimologia , Citoplasma/genética , Citoplasma/imunologia , Deleção de Genes , Genes Essenciais/imunologia , Interleucina-6/genética , Interleucina-6/imunologia , Interleucina-6/metabolismo , Leishmania donovani/genética , Leishmania donovani/imunologia , Leishmaniose Visceral/genética , Leishmaniose Visceral/imunologia , Macrófagos/imunologia , Macrófagos/parasitologia , Camundongos , Transporte Proteico , Proteínas de Protozoários/genética , Proteínas de Protozoários/imunologia , Receptores de Interleucina-8B/genética , Receptores de Interleucina-8B/imunologia , Receptores de Interleucina-8B/metabolismo , Fator de Necrose Tumoral alfa/genética , Fator de Necrose Tumoral alfa/imunologia , Fator de Necrose Tumoral alfa/metabolismo , Tirosina-tRNA Ligase/imunologia
10.
Sci Rep ; 6: 26603, 2016 05 25.
Artigo em Inglês | MEDLINE | ID: mdl-27221589

RESUMO

A library of arylidenefuropyridinediones was discovered as potent inhibitors of Leishmania donovani Topoisomerase 1 (LdTop1) where the active molecules displayed considerable inhibition with single digit micromolar EC50 values. This molecular library was designed via intuitive scaffold hopping and bioisosteric modification of known topoisomerase 1 inhibitors such as camptothecin, edotecarin and etc. The design was rationalized by molecular docking analysis of the compound prototype with human topoisomerase 1 (HTop1) and Leishmania donovani topoisomerase 1(LdTop1). The most active compound 4 displayed no cytotoxicity against normal mammalian COS7 cell line (~100 fold less inhibition at the EC50). Similar to camptothecin, 4 interacted with free LdTop1 as observed in the preincubation DNA relaxation inhibition experiment. It also displayed anti-protozoal activity against Leishmania donovani promastigote. Crystal structure investigation of 4 and its molecular modelling with LdTop1 revealed putative binding sites in the enzyme that could be harnessed to generate molecules with better potency.


Assuntos
DNA Topoisomerases Tipo I , Leishmania donovani/enzimologia , Leishmaniose Visceral , Modelos Moleculares , Proteínas de Protozoários , Inibidores da Topoisomerase I , Animais , Células COS , Chlorocebus aethiops , Cristalografia por Raios X , DNA Topoisomerases Tipo I/química , DNA Topoisomerases Tipo I/metabolismo , Leishmania donovani/genética , Leishmaniose Visceral/tratamento farmacológico , Leishmaniose Visceral/enzimologia , Proteínas de Protozoários/antagonistas & inibidores , Proteínas de Protozoários/metabolismo , Inibidores da Topoisomerase I/química , Inibidores da Topoisomerase I/farmacologia
11.
J Org Chem ; 81(8): 3149-60, 2016 Apr 15.
Artigo em Inglês | MEDLINE | ID: mdl-26999637

RESUMO

The synthesis of hitherto unreported S-alkyl/aryl benzothiazole-2-carbothioate is reported from thiols, oxalyl chloride, and 2-aminothiophenols using 10 mol % n-tetrabutylammonium iodide (TBAI) as catalyst in acetonitrile through multicomponent reaction (MCR) strategy. The present protocol favored formation of benzothiazoles and thioesters via simultaneous formation of C-N and C-S bonds in good yields with a wide range of substrates. A few of the synthesized derivatives were evaluated for their antimicrobial activity against the protozoan parasite Leishmania donovani, a causative agent of visceral leishmaniasis (VL). Further, these compounds displayed no toxicity toward macrophage RAW 264.7 cells and are therefore nontoxic and effective antileishmanial leads. In silico docking studies were performed to understand the possible binding site interaction with trypanothione reductase (TryR).


Assuntos
Antiprotozoários/síntese química , Antiprotozoários/farmacologia , Benzotiazóis/síntese química , Benzotiazóis/farmacologia , Leishmania donovani/efeitos dos fármacos , Macrófagos/efeitos dos fármacos , NADH NADPH Oxirredutases/química , NADH NADPH Oxirredutases/efeitos dos fármacos , Compostos de Sulfidrila/química , Antiprotozoários/química , Benzotiazóis/química , Sítios de Ligação , Leishmania donovani/enzimologia , Leishmaniose Visceral/enzimologia , NADH NADPH Oxirredutases/metabolismo , Ornitina Descarboxilase/metabolismo
12.
Exp Parasitol ; 157: 103-9, 2015 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-26208780

RESUMO

In C57BL/6 mice, Leishmania donovani infection in the liver provoked IFN-γ-induced expression of the immunity-related GTPases (IRG), Irgm1 and Irgm3. To gauge the antileishmanial effects of these macrophage factors in the liver, intracellular infection was analyzed in IRG-deficient mice. In early- (but not late-) stage infection, Irgm3(-/-) mice failed to properly control parasite replication, generated little tissue inflammation and were hyporesponsive to pentavalent antimony (Sb) chemotherapy. Observations limited to early-stage infection in Irgm1(-/-) mice demonstrated increased susceptibility and virtually no inflammatory cell recruitment to heavily-parasitized parenchymal foci but an intact response to chemotherapy. In L. donovani infection in the liver, the absence of either Irgm1 or Irgm3 impairs early inflammation and initial resistance; the absence of Irgm3, but not Irgm1, also appears to impair the intracellular efficacy of Sb chemotherapy.


Assuntos
GTP Fosfo-Hidrolases/metabolismo , Proteínas de Ligação ao GTP/metabolismo , Interferon gama/imunologia , Leishmania donovani/imunologia , Leishmaniose Visceral/imunologia , Hepatopatias Parasitárias/imunologia , Animais , Gluconato de Antimônio e Sódio/uso terapêutico , Antiprotozoários/uso terapêutico , Feminino , GTP Fosfo-Hidrolases/imunologia , Proteínas de Ligação ao GTP/imunologia , Regulação da Expressão Gênica , Leishmaniose Visceral/tratamento farmacológico , Leishmaniose Visceral/enzimologia , Fígado/enzimologia , Fígado/parasitologia , Fígado/patologia , Hepatopatias Parasitárias/tratamento farmacológico , Hepatopatias Parasitárias/enzimologia , Macrófagos/imunologia , Camundongos , Análise em Microsséries
13.
Br J Clin Pharmacol ; 80(5): 1160-8, 2015 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-25940755

RESUMO

AIMS: The aim of the present study was to investigate the impact of human visceral leishmaniasis (VL) and curative chemotherapy on the activity of cytochrome P450 (CYP) 3A, CYP2C9 and CYP2C19 in patients from an endemic region in Brazil. METHODS: Adult patients with parasitologically confirmed VL were given a CYP phenotyping cocktail, comprising midazolam, omeprazole and losartan, immediately before (Study phase 1), 2-3 days (phase 2) and 3-6 months (phase 3) after curative VL chemotherapy. CYP activity was assessed by the apparent clearance of midazolam (CYP3A), omeprazole/5-hydroxyomeprazol ratio in plasma (CYP2C19) and losartan/E3174 ratio in urine (CYP2C9). RESULTS: Mean values (95% confidence interval) in phases 1, 2 and 3 were, respectively: log apparent midazolam clearance, 1.21 (1.10-1.31), 1.45 (1.32-1.57) and 1.35 (1.26-1.44) ml min(-1) kg(-1) ; omeprazole/5-hydroxyomeprazole ratio, 0.78 (0.61-0.94), 0.45 (0.27-0.63) and 0.37 (0.20-0.55); losartan/E3174 ratio, 0.66 (0.39-0.92), 0.35 (0.20-0.50) and 0.35 (0.16-0.53). Analysis of variance revealed significant differences in CYP3A (P = 0.018) and CYP2C19 (P = 0.008), but not CYP2C9 (P = 0.11) phenotypic activity, across the three study phases. CONCLUSION: The phenotypic activities of CYP3A4 and CYP2C19 were significantly reduced during acute VL compared with post-chemotherapy. We propose that increased plasma concentrations of proinflammatory cytokines during active disease account for the suppression of CYP activity. The failure to detect significant changes in CYP2C9 activity in the overall cohort may reflect differential effects of the inflammatory process on the expression of CYP isoforms, although the possibility of insufficient statistical power cannot be dismissed.


Assuntos
Sistema Enzimático do Citocromo P-450/metabolismo , Leishmaniose Visceral/tratamento farmacológico , Leishmaniose Visceral/enzimologia , Losartan/farmacocinética , Midazolam/farmacocinética , Omeprazol/farmacocinética , Adolescente , Adulto , Brasil , Citocromo P-450 CYP2C19/metabolismo , Citocromo P-450 CYP2C9/metabolismo , Citocromo P-450 CYP3A/metabolismo , Feminino , Humanos , Losartan/urina , Masculino , Midazolam/sangue , Pessoa de Meia-Idade , Omeprazol/sangue , Adulto Jovem
14.
Mol Cell Biochem ; 404(1-2): 53-77, 2015 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-25763714

RESUMO

Leishmania are protozoan pathogens of humans that exist as extracellular promastigotes in the gut of their sand fly vectors and as obligate intracellular amastigotes within phagolysosomes of infected macrophages. Between infectious blood meal feeds, sand flies take plant juice meals that contain sucrose and store these sugars in their crop. Such sugars are regurgitated into the sand fly anterior midgut where they impact the developing promastigote parasite population. In this report we showed that promastigotes of all Leishmania species secreted an invertase/sucrase enzyme during their growth in vitro. In contrast, neither L. donovani nor L. mexicana amastigotes possessed any detectable invertase activity. Importantly, no released/secreted invertase activity was detected in culture supernatants from either Trypanosoma brucei or Trypanosoma cruzi. Using HPLC, the L. donovani secretory invertase was isolated and subjected to amino acid sequencing. Subsequently, we used a molecular approach to identify the LdINV and LmexINV genes encoding the ~72 kDa invertases produced by these organisms. Interestingly, we identified high fidelity LdINV-like homologs in the genomes of all Leishmania sp. but none were present in either T. brucei or T. cruzi. Northern blot and RT-PCR analyses showed that these genes were developmentally/differentially expressed in promastigotes but not amastigotes of these parasites. Homologous transfection studies demonstrated that these genes in fact encoded the functional secretory invertases produced by these parasites. Cumulatively, our results suggest that these secretory enzymes play critical roles in the survival/growth/development and transmission of all Leishmania parasites within their sand fly vector hosts.


Assuntos
Leishmania donovani/enzimologia , Leishmaniose Visceral/parasitologia , beta-Frutofuranosidase/genética , Sequência de Aminoácidos , Regulação Enzimológica da Expressão Gênica , Humanos , Leishmania donovani/crescimento & desenvolvimento , Leishmania donovani/patogenicidade , Leishmaniose Visceral/enzimologia , Leishmaniose Visceral/genética , Macrófagos/enzimologia , Macrófagos/parasitologia , Dados de Sequência Molecular , Trypanosoma cruzi/enzimologia , Trypanosoma cruzi/parasitologia , beta-Frutofuranosidase/biossíntese
15.
Biomed Res Int ; 2014: 264270, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-25309905

RESUMO

Visceral leishmaniasis (VL) is a chronic and fatal disease caused by Leishmania infantum in Brazil. Leukocyte recruitment to infected tissue is a crucial event for the control of infections such as VL. Leucotriens are lipid mediators synthesized by 5-lipoxygenase (5-LO) and they display a protective role against protozoan parasites by inducing several functions in leucocytes. We determined the role of 5-LO activity in parasite control, focusing on the inflammatory immune response against Leishmania infantum infection. LTB4 is released during in vitro infection. The genetic ablation of 5-LO promoted susceptibility in highly resistant mice strains, harboring more parasites into target organs. The susceptibility was related to the failure of neutrophil migration to the infectious foci. Investigating the neutrophil failure, there was a reduction of proinflammatory cytokines involved in the related Th17 axis released into the organs. Genetic ablation of 5-LO reduced the CD4(+)T cells producing IL-17, without interfering in Th1 subset. L. infantum failed to activate DC from 5-LO(-/-), showing reduced surface costimulatory molecule expression and proinflammatory cytokines involved in Th17 differentiation. BLT1 blockage with selective antagonist interferes with DC maturation and proinflammatory cytokines release. Thus, 5-LO activation coordinates the inflammatory immune response involved in the control of VL.


Assuntos
Araquidonato 5-Lipoxigenase/metabolismo , Leishmania infantum/fisiologia , Leishmaniose Visceral/enzimologia , Leishmaniose Visceral/imunologia , Substâncias Protetoras/metabolismo , Células Th17/imunologia , Animais , Araquidonato 5-Lipoxigenase/deficiência , Movimento Celular , Citocinas/metabolismo , Células Dendríticas/imunologia , Ativação Enzimática , Feminino , Interações Hospedeiro-Parasita/imunologia , Humanos , Leishmaniose Visceral/parasitologia , Leishmaniose Visceral/prevenção & controle , Masculino , Camundongos , Infiltração de Neutrófilos , Parasitos/fisiologia , Células Th1/imunologia
16.
PLoS Pathog ; 10(9): e1004347, 2014 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-25232945

RESUMO

Protozoan pathogens of the genus Leishmania have evolved unique signaling mechanisms that can sense changes in the host environment and trigger adaptive stage differentiation essential for host cell infection. The signaling mechanisms underlying parasite development remain largely elusive even though Leishmania mitogen-activated protein kinases (MAPKs) have been linked previously to environmentally induced differentiation and virulence. Here, we unravel highly unusual regulatory mechanisms for Leishmania MAP kinase 10 (MPK10). Using a transgenic approach, we demonstrate that MPK10 is stage-specifically regulated, as its kinase activity increases during the promastigote to amastigote conversion. However, unlike canonical MAPKs that are activated by dual phosphorylation of the regulatory TxY motif in the activation loop, MPK10 activation is independent from the phosphorylation of the tyrosine residue, which is largely constitutive. Removal of the last 46 amino acids resulted in significantly enhanced MPK10 activity both for the recombinant and transgenic protein, revealing that MPK10 is regulated by an auto-inhibitory mechanism. Over-expression of this hyperactive mutant in transgenic parasites led to a dominant negative effect causing massive cell death during amastigote differentiation, demonstrating the essential nature of MPK10 auto-inhibition for parasite viability. Moreover, phosphoproteomics analyses identified a novel regulatory phospho-serine residue in the C-terminal auto-inhibitory domain at position 395 that could be implicated in kinase regulation. Finally, we uncovered a feedback loop that limits MPK10 activity through dephosphorylation of the tyrosine residue of the TxY motif. Together our data reveal novel aspects of protein kinase regulation in Leishmania, and propose MPK10 as a potential signal sensor of the mammalian host environment, whose intrinsic pre-activated conformation is regulated by auto-inhibition.


Assuntos
Retroalimentação Fisiológica , Proteínas de Fluorescência Verde/metabolismo , Leishmania donovani/enzimologia , Leishmaniose Visceral/parasitologia , Proteínas Quinases Ativadas por Mitógeno/metabolismo , Sequência de Aminoácidos , Western Blotting , Sobrevivência Celular , Células Cultivadas , Proteínas de Fluorescência Verde/genética , Humanos , Leishmania donovani/crescimento & desenvolvimento , Leishmania donovani/patogenicidade , Leishmaniose Visceral/enzimologia , Leishmaniose Visceral/patologia , Proteínas Quinases Ativadas por Mitógeno/genética , Dados de Sequência Molecular , Fosforilação , Homologia de Sequência de Aminoácidos
17.
Ann Saudi Med ; 34(2): 143-6, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-24894783

RESUMO

BACKGROUND AND OBJECTIVES: Visceral leishmaniasis (VL) is a life-threatening infection caused by Leishmania species. In Sudan, VL is caused by L donovani. Most drugs used to treat VL, especially pentavalent antimony compounds (sodium stibogluconate, SSG), are potentially hepatotoxic. A number of fatal catastrophes happened because patients with VL-hepatitis B/C coinfection were indiscriminately treated with SSG in settings where VL and viral hepatitis coexist. This study aimed to study biochemical and hematological parameters of patients with VL-hepatitis B/C coinfections with the aim to modify treatment protocols to reduce coinfection.added morbidity and mortality. DESIGN AND SETTINGS: This was a prospective analytical, hospital-based, and case-controlled study. The study was done at Kassab Hospital and Professor Elhassan Centre for tropical medicine during the period of February 2008 to April 2013. MATERIALS AND METHODS: Following informed consent by the participants, 78 parasitologically confirmed VL patients with either hepatitis B or C or both and 528 sex- and age-unmatched VL patients without hepatitis B/C coinfection (control group) were enrolled sequentially. Diagnosis of hepatitis B or C was made using immunochromatographic test kits and confirmed by an enzyme-linked immunosorbent assay. RESULTS: VL patients with hepatitis B/C coinfections had significantly increased levels of AST, ALT, and total bilirubin compared to the control group (P=.0001 for all), with significantly decreased levels of albumin and platelets counts (P=.0029 for both). CONCLUSION: VL-hepatitis B/C coinfections are an emerging entity that needs anti-leishmanial treatment modification. Alternative treatments like paromomycin and amphotericin B (AmBisome) could be reserved for these patients.


Assuntos
Coinfecção/sangue , Hepatite B/sangue , Hepatite C/sangue , Leishmaniose Visceral/sangue , Adolescente , Adulto , Alanina Transaminase/sangue , Albuminas/análise , Antiprotozoários/efeitos adversos , Aspartato Aminotransferases/sangue , Bilirrubina/sangue , Estudos de Casos e Controles , Criança , Coinfecção/enzimologia , Ensaio de Imunoadsorção Enzimática , Feminino , Hepatite B/complicações , Hepatite B/enzimologia , Hepatite C/complicações , Hepatite C/enzimologia , Hospitais , Humanos , Leishmaniose Visceral/complicações , Leishmaniose Visceral/tratamento farmacológico , Leishmaniose Visceral/enzimologia , Masculino , Contagem de Plaquetas , Estudos Prospectivos , Resultado do Tratamento , Triagem , Adulto Jovem
18.
Cell Mol Immunol ; 11(3): 263-74, 2014 May.
Artigo em Inglês | MEDLINE | ID: mdl-24561457

RESUMO

Fucoidan can cure both antimony-sensitive and antimony-resistant visceral leishmaniasis through immune activation. However, the signaling events underlying this cellular response remain uncharacterized. The present study reveals that fucoidan induces activation of p38 and ERK1/2 and NF-κB DNA binding in both normal and Leishmania donovani-infected macrophages, as revealed by western blotting and electrophoretic mobility shift assay (EMSA), respectively. Pharmacological inhibition of p38, ERK1/2 or the NF-κB pathway markedly attenuated fucoidan-induced pro-inflammatory cytokine synthesis and inducible nitric oxide synthase (iNOS) gene transcription, resulting in a reduction of parasite clearance. To decipher the underlying mechanism of fucoidan-mediated parasite suppression, the expression and functionality of various protein kinase C (PKC) isoforms were evaluated by immunoblotting and enzyme activity assay. Fucoidan elicited an increase in expression and activity of PKC-α, -ßI and -ßII isoforms in infected macrophages. Functional knockdown of PKC-α and -ß resulted in downregulation of p38 and ERK1/2, along with a marked reduction of IL-12 and TNF-α production in fucoidan-treated infected macrophages. Collectively, these results suggest that the curative effect of fucoidan is mediated by PKC-dependent activation of the mitogen-activated protein kinase (MAPK)/NF-κB pathway, which ultimately results in the production of nitric oxide (NO) and disease-resolving pro-inflammatory cytokines.


Assuntos
Leishmaniose Visceral/tratamento farmacológico , Leishmaniose Visceral/enzimologia , Proteínas Quinases Ativadas por Mitógeno/metabolismo , Polissacarídeos/uso terapêutico , Proteína Quinase C/metabolismo , Animais , Anticorpos Monoclonais/farmacologia , Anticorpos Monoclonais/uso terapêutico , Linhagem Celular , Ativação Enzimática/efeitos dos fármacos , Imunidade/efeitos dos fármacos , Mediadores da Inflamação/metabolismo , Isoenzimas/metabolismo , Leishmania donovani/efeitos dos fármacos , Leishmaniose Visceral/imunologia , Leishmaniose Visceral/parasitologia , Sistema de Sinalização das MAP Quinases/efeitos dos fármacos , Camundongos Endogâmicos BALB C , NF-kappa B/metabolismo , Óxido Nítrico Sintase Tipo II/metabolismo , Polissacarídeos/farmacologia , Tiazinas/farmacologia , Fator de Transcrição AP-1/metabolismo
19.
PLoS One ; 8(11): e79287, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-24260187

RESUMO

Casein kinase 1 (CK1) plays an important role in eukaryotic signaling pathways, and their substrates include key regulatory proteins involved in cell differentiation, proliferation and chromosome segregation. The Leishmania genome encodes six potential CK1 isoforms, of which five have orthologs in other trypanosomatidae. Leishmania donovani CK1 isoform 4 (Ldck1.4, orthologous to LmjF27.1780) is unique to Leishmania and contains a putative secretion signal peptide. The full-length gene and three shorter constructs were cloned and expressed in E. coli as His-tag proteins. Only the full-length 62.3 kDa protein showed protein kinase activity indicating that the N-terminal and C-terminal domains are essential for protein activity. LdCK1.4-FLAG was stably over expressed in L. donovani, and shown by immunofluorescence to be localized primarily in the cytosol. Western blotting using anti-FLAG and anti-CK1.4 antibodies showed that this CK1 isoform is expressed and secreted by promastigotes. Over expression of LdCK1.4 had a significant effect on promastigote growth in culture with these parasites growing to higher cell densities than the control parasites (wild-type or Ld:luciferase, P<0.001). Analysis by flow cytometry showed a higher percentage, ∼4-5-fold, of virulent metacyclic promastigotes on day 3 among the LdCK1.4 parasites. Finally, parasites over expressing LdCK1.4 gave significantly higher infections of mouse peritoneal macrophages compared to wild-type parasites, 28.6% versus 6.3%, respectively (p = 0.0005). These results suggest that LdCK1.4 plays an important role in parasite survival and virulence. Further studies are needed to validate CK1.4 as a therapeutic target in Leishmania.


Assuntos
Caseína Quinase I/biossíntese , Regulação Enzimológica da Expressão Gênica , Leishmania donovani/enzimologia , Leishmania donovani/patogenicidade , Leishmaniose Visceral/enzimologia , Proteínas de Protozoários/biossíntese , Fatores de Virulência/biossíntese , Animais , Caseína Quinase I/genética , Leishmania donovani/genética , Leishmaniose Visceral/genética , Macrófagos Peritoneais/enzimologia , Macrófagos Peritoneais/parasitologia , Macrófagos Peritoneais/patologia , Camundongos , Camundongos Endogâmicos BALB C , Estrutura Terciária de Proteína , Proteínas de Protozoários/genética , Fatores de Virulência/genética
20.
Vet Immunol Immunopathol ; 148(3-4): 260-6, 2012 Aug 15.
Artigo em Inglês | MEDLINE | ID: mdl-22673195

RESUMO

Matrix metalloproteinases (MMPs) are a group of calcium- and zinc-dependent endopeptidases that are involved in maintaining the extracellular matrix. MMP-2 and MMP-9 are thought to be related to the disruption of the blood-brain-barrier (BBB) by their ability to cleave type IV collagen, the main component of the basal membrane. To establish the presence of MMP-2 and MMP-9 in the pathogenesis of canine cerebral leishmaniasis, we examined the levels of these metalloproteinases in the cerebrospinal fluid (CSF) and serum of dogs with visceral leishmaniasis and neurological symptoms (n=16) and in the CSF and serum of uninfected healthy dogs (n=10) using zymography. In the CSF of dogs with cerebral leishmaniasis there was a massive presence of active MMP-2, whereas only the levels of both proMMP-2 and proMMP-9 were elevated in the serum. Although the detected MMP activity in the CSF might merely be related to CNS inflammation, these enzymes may also play a collaborative role in the disease progression. Both MMP-2 and MMP-9 are known to target critical constituents of the BBB, and once activated, they may promote cerebral barrier breakdown, allowing the entrance of inflammatory cells and proteins within the nervous system milieu.


Assuntos
Infecções Protozoárias do Sistema Nervoso Central/veterinária , Doenças do Cão/parasitologia , Leishmaniose Visceral/veterinária , Metaloproteinase 2 da Matriz/fisiologia , Animais , Infecções Protozoárias do Sistema Nervoso Central/enzimologia , Progressão da Doença , Doenças do Cão/enzimologia , Cães , Precursores Enzimáticos/sangue , Precursores Enzimáticos/líquido cefalorraquidiano , Precursores Enzimáticos/fisiologia , Feminino , Gelatinases/sangue , Gelatinases/líquido cefalorraquidiano , Gelatinases/fisiologia , Leishmaniose Visceral/enzimologia , Masculino , Metaloproteinase 2 da Matriz/sangue , Metaloproteinase 2 da Matriz/líquido cefalorraquidiano , Metaloproteinase 9 da Matriz/sangue , Metaloproteinase 9 da Matriz/líquido cefalorraquidiano , Metaloproteinase 9 da Matriz/fisiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA